Compare
West Pharmaceutical Services Inc vs Teleflex Inc vs ResMed Inc vs Integra Lifesciences Holdings Corp
| Latest fiscal year | West Pharmaceutical Services Inc WST | Teleflex Inc TFX | ResMed Inc RMD | Integra Lifesciences Holdings Corp IART |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $3.07B | $1.99B | $5.65B | $1.64B |
| Revenue growth (YoY) | +6.3% | +17.2% | +9.9% | +1.5% |
| Gross margin | 35.9% | 56.2% | 61.1% | 50.9% (computed) |
| Operating margin | 19.0% | 5.9% | 33.4% | -30.2% |
| Net margin | 16.1% | -45.4% | 26.9% | -31.6% |
| Net income | $493.70M | -$905.64M | $1.52B | -$516.47M |
| EPS (Diluted) | $6.79 | -$20.25 | $10.43 | -$6.74 |
| Operating cash flow | $754.80M | $96.68M | $1.81B | $50.38M |
| Free cash flow | $468.90M | $1.45M | $1.65B | -$31.05M |
| Cash & equivalents | $791.30M | $378.56M | $1.47B | $235.05M |
| Total assets | $4.27B | $6.95B | $8.97B | $3.60B |
| Total liabilities | $1.09B | $3.82B | $2.38B | $2.56B |
| Shareholders' equity | $3.18B | $3.12B | $6.59B | $1.04B |
| Return on year-end equity | 15.5% | -29.0% | 23.1% | -49.5% |
| Shares outstanding | 72.00M | n/a | 144.24M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | West Pharmaceutical Services Inc | Teleflex Inc | ResMed Inc | Integra Lifesciences Holdings Corp |
|---|---|---|---|---|
| Latest | $3.07B Ended 2025-12-31 | $1.99B Ended 2025-12-31 | $5.65B Ended 2026-06-30 | $1.64B Ended 2025-12-31 |
| 1 year earlier | $2.89B Ended 2024-12-31 | $1.70B Ended 2024-12-31 | $5.15B Ended 2025-06-30 | $1.61B Ended 2024-12-31 |
| 2 years earlier | $2.95B Ended 2023-12-31 | $1.71B Ended 2023-12-31 | $4.69B Ended 2024-06-30 | $1.54B Ended 2023-12-31 |
| 3 years earlier | $2.89B Ended 2022-12-31 | $2.79B Ended 2022-12-31 | $4.22B Ended 2023-06-30 | $1.56B Ended 2022-12-31 |
| 4 years earlier | $2.83B Ended 2021-12-31 | $2.81B Ended 2021-12-31 | $3.58B Ended 2022-06-30 | $1.54B Ended 2021-12-31 |